Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Genelux Corp GNLX

Healthcare Biotechnology
Genelux Corporation is a late clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a... see more

Recent & Breaking News (NDAQ:GNLX)

    Genelux Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

    GlobeNewswire April 1, 2024

    Genelux Corporation Receives FDA Fast Track Designation for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer

    GlobeNewswire November 27, 2023

    Genelux Corporation Reports Third Quarter 2023 Financial Results and Provides General Business Updates

    GlobeNewswire November 14, 2023

    Genelux Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    GlobeNewswire September 14, 2023

    Genelux Corporation to Present at the H.C. Wainwright Global Investment Conference

    GlobeNewswire September 7, 2023

    Genelux Corporation Announces New Chief Financial Officer

    GlobeNewswire August 28, 2023

    Genelux Corporation Reports Second Quarter 2023 Financial Results and Provides General Business Updates

    GlobeNewswire August 14, 2023

    Genelux Corporation to Participate in Fireside Chat at BTIG's Virtual Biotechnology Conference 2023

    GlobeNewswire August 2, 2023

    Genelux Corporation Strengthens Senior Management and Clinical Team with Promotions and New Hires

    GlobeNewswire July 20, 2023

    Genelux Corporation Announces Publication of Phase I Trial Results of Intrapleural Administration of Olvi-Vec in Patients with Malignant Pleural Effusion from Mesothelioma, Lung or Breast Cancers in Frontiers in Immunology

    GlobeNewswire July 10, 2023

    Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics(TM), LLC

    GlobeNewswire June 29, 2023

    Genelux Corporation Set to Join the Russell 3000® and Russell 2000® Indexes Effective June 26, 2023

    GlobeNewswire June 22, 2023

    Genelux Corporation Announces $18 Million Private Placement

    GlobeNewswire June 12, 2023

    Genelux Corporation Announces Publication of Positive Topline Data from Phase 2 VIRO-15 Trial Evaluating Olvimulogene Nanivacirepvec (Olvi-Vec) in Platinum-Resistant or Refractory Ovarian Cancer in the Journal of the American Medical Association (JAMA) Oncology

    GlobeNewswire May 25, 2023

    Genelux Corporation Announces $33 Million Private Placement

    GlobeNewswire May 15, 2023

    Genelux Corporation to Ring Nasdaq Opening Bell on March 29, 2023

    GlobeNewswire March 23, 2023